



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: David Polinsky
Cornerstone Pharmaceuticals, Inc.
(609) 409 -7050 ext 202
news@cornerstonepharma.com

**CORNERSTONE PHARMACEUTICALS ANNOUNCES PUBLICATION OF CASE REPORT
ON TREATMENT OF A PATIENT PRESENTING METASTATIC PANCREATIC CANCER
WITH CPI-613 AND GEMCITABINE COMBINATION THERAPY**

CRANBURY, NJ (April 30, 2012) Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the publication of a paper in *Case Study and Case Report* (<http://cscr.scopemed.org/>) describing the treatment of a patient presenting metastatic pancreatic cancer with a combination of gemcitabine and Cornerstone's investigational new drug directed against mitochondrial cancer cell metabolism, CPI-613. The patient was treated as part of Cornerstone's Phase I clinical trial designed to assess this combination. The paper is entitled "Pseudo-Progression of Metastatic Pancreatic Cancer Assessed by Imaging Studies – A Case Report" and is available online at: <http://www.scopemed.org/?mno=22371>.

Specifically, the case study describes how a 78-year old female African-American patient presenting ductal carcinoma in situ and metastatic pancreatic cancer was treated with CPI-613 in combination with gemcitabine. The patient opted out of all treatment after two cycles and exhibited disease progression according to CT scan. However, FDG-PET showed a reduction of Standardized Uptake Values (SUV) of the target lesions, and the relevant biomarker CA 19-9 was similarly reduced. The patient is still alive after over two years, has no clinical signs of disease progression, and has good performance status. Thus, CT scan can provide pseudo-progression diagnosis, as confirmed with reduced SUV by PET, reduced CA 19-9, and prolonged survival. The report concluded that imaging studies should be used cautiously and skeptically in assessing treatment response.

Robert Shorr, Ph.D., Chief Executive Officer of Cornerstone Pharmaceuticals, commented that "This particular case study proved valuable not only in demonstrating that CPI-613 in combination with gemcitabine exhibits the potential to be clinically useful against advanced pancreatic cancer, but also that the imaging response to this therapy is more complex than it initially appears. It is possible that other cancer patients who appear to exhibit disease progression using only one modality of imaging may in fact be responding well to treatment, and clinicians must take this phenomenon into account before discontinuing a particular avenue of therapy."



CPI-613 is the lead drug candidate from Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) platform. Cornerstone's AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as the company's lead drug CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in a Phase I trial.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. www.cornerstonepharma.com

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.